Organization
GlaxoSmithKline, Collegeville, United States of America
1 abstract
Abstract
A PHASE 3, OPEN-LABEL, CONTINUATION STUDY EVALUATING LONG-TERM SAFETY AND EFFICACY OF BELIMUMAB IN PATIENTS FROM JAPAN AND KOREA WITH SYSTEMIC LUPUS ERYTHEMATOSUS, FOR UP TO 7 YEARSOrg: University of Occupational and Environmental Health, Kitakyushu, Japan, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Rep. of (South Korea), GlaxoSmithKline, Collegeville, United States of America, GlaxoSmithKline (at the time of the study), Collegeville, United States of America, GlaxoSmithKline, Uxbridge, United Kingdom,